Omzet 2024 * | 688 mln. 634 mln. | Omzet 2025 * | 847 mln. 780 mln. | Marktkapitalisatie | 3,51 mld. 3,24 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -107 mln. -98,52 mln. | Nettowinst (verlies) 2025 * | -1 mln. -921K | EV/omzet 2024 * | 4,82 x |
Nettoliquiditeiten 2024 * | 199 mln. 183 mln. | Nettoliquiditeiten 2025 * | 306 mln. 281 mln. | EV/omzet 2025 * | 3,79 x |
K/w-verhouding 2024 * |
-31,1
x | K/w-verhouding 2025 * |
421
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 52,37% |
Recentste transcriptie over HUTCHISON CHINA MED.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 01-01-05 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 01-07-08 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Graeme Jack
BRD | Director/Board Member | 73 | 01-03-17 |
Dan Eldar
CHM | Chairman | 70 | 01-08-16 |
Edith Shih
BRD | Director/Board Member | 71 | 01-01-00 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+34,35% | 693 mld. | |
+29,39% | 584 mld. | |
-3,49% | 372 mld. | |
+20,15% | 332 mld. | |
+6,19% | 294 mld. | |
+14,11% | 239 mld. | |
-3,03% | 211 mld. | |
+10,02% | 210 mld. | |
+9,21% | 168 mld. |